Business Wire

ADVA

24.3.2021 08:02:08 CET | Business Wire | Press release

Share
Vodafone Romania uses ADVA NOS in trial of DCSG

ADVA (FSE: ADV) today announced that Vodafone Romania is using its carrier-grade network operating system (NOS) in a key trial of disaggregated cell site gateway (DCSG) technology in a live nationwide network. Built with ADVA’s Ensemble Activator software running on Edgecore’s new family of DCSG devices, the open multi-vendor transport network succeeded in carrying 2G, 3G, 4G and 5G traffic while also interoperating with Vodafone’s existing infrastructure. The trial is a key step towards Vodafone validating the disaggregated model.

“We are pleased to contribute to the innovation in the field of open telecom networks, facilitating the validation of the open cell site gateway concept in a live network scenario while following our existing standard practices and processes. It was a smooth introduction, proving that the concept of open telecom networks where hardware is decoupled from software is feasible – not only in core network platforms through virtualization and in mobile radio access networks through the OpenRAN, but now also in the IP transport layer,” said Catalin Buliga, CTO, Vodafone Romania. “Mobile networks have been for years locked into a limited number of traditional telecom equipment vendors. By investing in developing open networks, where the hardware and software are decoupled, we open the gate to a wide range of suppliers for hardware, a wide range of suppliers for software, we accelerate innovation and increase our resilience.”

By using ADVA and Edgecore’s technology in a complete and fully tested DCSG offering, the trial gives Vodafone Romania insight into new mobile transport opportunities. Developed within the Telecom Infra Project’s Open Optical & Packet Transport group, the solution provides an open, agile and scalable solution able to meet today’s protocol requirements and is adaptable with future needs. Its hardware-supported SyncE and IEEE 1588 timing, with optional SFP-based GNSS backup, fulfills the most stringent synchronization accuracy requirements.

“This latest trial highlights how major mobile network operators have an alternative simple and cost-effective route to the deployment for 5G services. Our open and feature-rich Ensemble Activator NOS and Edgecore’s high-performance white boxes free network operators from closed proprietary systems. They enable them to deploy vendor-neutral disaggregated architectures using best-in-class components,” commented Eli Angel, VP, product line management, ADVA. “Today’s customers expect vendors to work side by side and build open solutions that can easily fit into complex heterogeneous environments. But while some in the industry do little more than talk about their commitment to collaboration and openness, we’re continually proving it. Now, trials like this are making the value of our approach abundantly clear.”

“As the leading provider of open network solutions to Tier 1 operators worldwide, and the leading contributor to the OCP, ONF, and TIP open communities, Edgecore understands the requirement to accelerate the innovation of disaggregated open network deployments while moving toward a more consistent and open infrastructure across mobile broadband and transport networks,” noted George Tchaparian, CEO and president, Edgecore Networks. “This successful live trial in Romania is yet another proof point that open networking is robust and deployable in the most demanding network environments.”


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/pages/ADVA-Optical-Networking/37630238931

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye